This study evaluates the efficacy of the endoscopic hemostatic powder for the treatment of bleeding from malignant lesions of the upper GI tract. Half of participants will receive hemostatic powder and half will be submitted to standard treatment.
Gastrointestinal tumor bleeding is a challenging clinical condition with a high mortality rate. Several endoscopic hemostasis techniques have been tested, but results were disappointing. Re-bleeding and mortality rates are still high. Hemostatic powder is a promising therapy for tumor bleeding, since it can be applied over large surfaces. Bleeding from a tumor lesion often occurs diffusely on the surface of the tumor rather than from a specific vessel.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
62
Malignant bleeding lesions will be treated with endoscopic powder and patients will receive optical clinical management afterwards
rebleeding
Time frame: until 30 days after endoscopy
mortality
Time frame: until 30 days after endoscopy
Successful initial hemostasis
Time frame: From the moment of the procedure until 24 hours after it
Hospital length of stay
Time frame: from the moment of the endoscopic procedure until hospital discharge or death, whichever came first, assessed up to 100 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.